Q32 Bio announced that it has received a Fast Track designation for bempikibart, its investigational treatment for alopecia areata (AA),…
There was good news for Sun Pharmaceutical Industries, Ltd. (Sun Pharma) and the alopecia areata community in the form of…
NAAF is thrilled to announce the recipients of the 2024 Early Career Awards and Research Grants! Three investigators have been…
We are thrilled to announce that Philadelphia is now a second Flagship Site for the 2025 Walk For Alopecia…
Alopecia areata (AA) took center stage at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. NAAF…
This past July, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, making it the third…
The National Alopecia Areata Foundation (NAAF) is proud to announce its 2nd Annual Walk For Alopecia™ has exceeded its $900,000…
Last year, Nicole Friedland, NAAF President and CEO, participated in an expert steering committee, the Alopecia Areata Consensus Task Force,…
Today, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking the third FDA-approved treatment for…
NAAF awards research grants to researchers with promising proposals to learn more about alopecia areata – what is happening in…
